Celsion Corporation to Present at NobleConXV – Noble Capital Markets’ 15th Annual Investor Conference
24 janv. 2019 11h30 HE
|
Celsion CORP
LAWRENCEVILLE, N.J., Jan. 24, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that Jeffrey Church, Celsion’s Executive Vice...
Celsion Announces Publication of ThermoDox® Study Results in Radiology
17 janv. 2019 08h30 HE
|
Celsion CORP
Publication Highlights Phase I Data Supporting Safety and Feasibility of Treatment with ThermoDox® and Non-Invasive, Focused Ultrasound University of Oxford’s Findings Provide Additional...
Celsion Corporation to Hold Second Quarter 2018 Financial Results Conference Call on Tuesday, August 14, 2018
07 août 2018 09h00 HE
|
Celsion CORP
LAWRENCEVILLE, N.J, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter...
CELSION ANNOUNCES PUBLICATION OF THERMODOX® PHASE I CLINICAL STUDY RESULTS IN THE LANCET ONCOLOGY
10 juil. 2018 08h00 HE
|
Celsion CORP
– The TARDOX Study, in Collaboration with University of Oxford, Evaluates the Use of Focused Ultrasound in Combination with ThermoDox® to Treat Primary and Metastatic Liver Cancer – – Imaging...